CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $114.06M, lower than 95% of all stocks globally
- PositionReturn on equity is -222%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
162.56BKRW114.06M · vs all stocks (USD)
Revenue (TTM)
2.79BKRW1.96M · vs all stocks (USD)
Beta
-0.0120xvs all stocks
52-Week Change
-14.80%vs all stocks
Market Capitalization
162.56BKRW114.06M · vs all stocks (USD)
Enterprise Value
131.86BKRW92.52M · vs all stocks (USD)
Price to Sales (TTM)
53.30xvs Biotechnology peers
Price to Book (MRQ)
7.25xvs Biotechnology peers
Enterprise to Revenue
47.30xvs Biotechnology peers
Enterprise to EBITDA
-14.79xvs Biotechnology peers
Gross Margin
48.80%vs Biotechnology peers
Operating Margin
-1376.41%vs Biotechnology peers
Return on Assets (TTM)
-18.45%vs Biotechnology peers
Return on Equity (TTM)
-221.97%vs Biotechnology peers
Revenue (TTM)
2.79BKRW1.96M · vs all stocks (USD)
Revenue per Share (TTM)
186.05KRWUpdated Jul 15, 2026Quarterly Revenue Growth
-30.80%vs Biotechnology peers
Gross Profit (TTM)
2.19BKRW1.54M · vs all stocks (USD)
EBITDA (TTM)
-8.92BKRW-6.26M · vs all stocks (USD)
Net Income (TTM)
-44.46BKRW-31.20M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-30.77%vs Biotechnology peers
Operating Cash Flow (TTM)
-6.51BKRW-4.57M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.03BKRW-4.93M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.91BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
532.32MKRWFY2025 · Dec 31, 2025Gross Profit
2.38BKRWFY2025 · Dec 31, 2025Operating Income
-9.27BKRW-6.50M · vs all stocks (USD)
Pre-tax Income
-42.02BKRWFY2025 · Dec 31, 2025Net Income
-42.02BKRWFY2025 · Dec 31, 2025EBIT
-40.77BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.26BKRWFY2025 · Dec 31, 2025Research & Development
6.78BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.15BKRWFY2025 · Dec 31, 2025Other Operating Expenses
200.73MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
546.53MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.26BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-42.02BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-40.21BKRWFY2025 · Dec 31, 2025Free Cash Flow
-41.23BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
38.92BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-42.02BKRWFY2025 · Dec 31, 2025Stock-based Compensation
587.82MKRWFY2025 · Dec 31, 2025Other Non-cash Items
1.30BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-169.90MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
96.78MKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.02BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-400.00MKRWFY2025 · Dec 31, 2025Purchase of Investments
-66.77BKRWFY2025 · Dec 31, 2025Sale of Investments
66.84BKRWFY2025 · Dec 31, 2025Other Investing Activity
-325.93MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.27BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
35.00BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-500.00MKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-500.00MKRWFY2025 · Dec 31, 2025Other Financing Charges
230.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
37.44BKRWFY2025 · Dec 31, 2025Shares Outstanding
15.18MSharesUpdated Jul 15, 2026Float Shares
10.65MSharesUpdated Jul 15, 2026% Held by Insiders
29.04%vs all stocks
% Held by Institutions
1.41%vs all stocks
Total Cash (MRQ)
41.17BKRW28.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.71KKRWUpdated Jul 15, 2026Total Debt (MRQ)
15.63BKRW10.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6972xvs Biotechnology peers
Current Ratio (MRQ)
16.45xvs Biotechnology peers
Book Value per Share (MRQ)
1.48KKRWUpdated Jul 15, 2026Total Assets
55.80BKRW39.15M · vs all stocks (USD)
Total Current Assets
44.81BKRWFY2025 · Dec 31, 2025Total Liabilities
29.20BKRWFY2025 · Dec 31, 2025Total Non-current Assets
10.98BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
27.96BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.24BKRWFY2025 · Dec 31, 2025Cash Equivalents
38.92BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
38.92BKRWFY2025 · Dec 31, 2025Other Short-term Investments
5.35BKRWFY2025 · Dec 31, 2025Accounts Receivable
25.96MKRWFY2025 · Dec 31, 2025Accounts Payable
266.00KKRWFY2025 · Dec 31, 2025Short-term Debt
181.00MKRWFY2025 · Dec 31, 2025Other Current Liabilities
-270.00KRWFY2025 · Dec 31, 2025Long-term Debt
14.51BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
170.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
7.59BKRWFY2025 · Dec 31, 2025Retained Earnings
-162.32BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
26.60BKRW18.66M · vs all stocks (USD)
52-Week Low
9.00KKRWUpdated Jul 15, 202652-Week High
38.00KKRWUpdated Jul 15, 202652-Week Change
-14.80%vs all stocks
Beta
-0.0120xvs all stocks
50-Day MA
15.95KKRWUpdated Jul 15, 2026200-Day MA
21.85KKRWUpdated Jul 15, 2026Avg 10-Day Volume
86.92KSharesUpdated Jul 15, 2026Avg 30-Day Volume
108.44KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-2.82KKRWUpdated Jul 15, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -222%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.22Industry median: -0.22Industry P5: -1.66Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 16.45Altman Z-Score: -2.15
Financial Health
Altman Z-Score -2.15: distress zoneCritical
Altman Z-Score: -2.15
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $114.06M, lower than 95% of all stocks globallySignificant
Market cap (USD): 114,059,918.288Global P5: 269,387,740.27
Revenue is $1.96M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,955,999.058Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Great Microwave Technology Co., Ltd.
4 interpretationsLiquidity Ratios ElevatedDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsPartial Recovery After Sharp Decline
Oddity Tech Ltd.
4 interpretationsLiquidity Ratios ElevatedDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsPartial Recovery After Sharp Decline
GoldQuest Mining Corp.
4 interpretationsLiquidity Ratios ElevatedDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsPartial Recovery After Sharp Decline